高剂量三价与标准剂量四价流感疫苗对高危心血管病患者死亡或心肺住院的影响:一项随机临床试验
该随机临床试验纳入5260例高危心血管病患者,比较高剂量三价与标准剂量四价流感疫苗对全因死亡或心肺住院复合终点的影响。高剂量组疫苗相关不良反应更常见,但严重不良反应发生率低。
要点
- 高剂量三价疫苗未显著降低高危心血管病患者全因死亡或心肺住院风险。
- 高剂量组疫苗相关不良反应发生率40.5%,标准剂量组34.4%。
- 该人群仍应强烈推荐接种流感疫苗。
核心结论
- 在高危心血管病患者中,高剂量三价灭活流感疫苗相比标准剂量四价灭活流感疫苗未显著降低全因死亡或心肺住院复合终点。
- 流感疫苗接种在该人群中仍被强烈推荐。
研究设计与样本
- 实用性多中心、双盲、活性对照随机临床试验,于美国和加拿大157个中心开展。
- 共纳入5260例近期发生急性心肌梗死或心力衰竭住院且至少合并1项额外危险因素的患者。
- 参与者随机接受高剂量三价(n=2630)或标准剂量四价(n=2630)灭活流感疫苗,最多可接种3个流感季。
- 主要终点为每个入组流感季期间全因死亡或心肺住院的复合终点时间。
主要发现
- 高剂量组发生975例主要终点事件(883例心血管或肺部原因住院,92例全因死亡),事件率45/100患者年。
- 标准剂量组发生924例主要终点事件(846例心血管或肺部原因住院,78例全因死亡),事件率42/100患者年。
- 高剂量组疫苗相关不良反应发生率为40.5%(1449例),标准剂量组为34.4%(1229例)。
- 高剂量组严重不良反应发生率为2.1%(55例),标准剂量组为1.7%(44例)。
临床怎么用
- 对于近期发生急性心肌梗死或心力衰竭住院的高危心血管病患者,不应为追求额外保护而常规选用高剂量三价流感疫苗替代标准剂量四价疫苗。
- 临床应继续按照指南强烈推荐该人群接种流感疫苗,具体剂型可依据可及性和耐受性选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Influenza is temporally associated with cardiopulmonary morbidity and mortality among those with cardiovascular disease who may mount a less vigorous immune response to vaccination. Higher influenza vaccine dose has been associated with reduced risk of influenza illness. OBJECTIVE: To evaluate whether high-dose trivalent influenza vaccine compared with standard-dose quadrivalent influenza vaccine would reduce all-cause death or cardiopulmonary hospitalization in high-risk patients with cardiovascular disease. DESIGN, SETTING, AND PARTICIPANTS: Pragmatic multicenter, double-blind, active comparator randomized clinical trial conducted in 5260 participants vaccinated for up to 3 influenza seasons in 157 sites in the US and Canada between September 21, 2016, and January 31, 2019. Patients with a recent acute myocardial infarction or heart failure hospitalization and at least 1 additional risk factor were eligible. INTERVENTIONS: Participants were randomly assigned to receive high-dose trivalent (n = 2630) or standard-dose quadrivalent (n = 2630) inactivated influenza vaccine and could be revaccinated for up to 3 seasons. MAIN OUTCOMES AND MEASURES: The primary outcome was the time to the composite of all-cause death or cardiopulmonary hospitalization during each enrolling season. The final date of follow-up was July 31, 2019. Vaccine-related adverse events were also assessed. RESULTS: Among 5260 randomized participants (mean [SD] age, 65.5 [12.6] years; 3787 [72%] men; 3289 [63%] with heart failure) over 3 influenza seasons, there were 7154 total vaccinations administered and 5226 (99.4%) participants completed the trial. In the high-dose trivalent vaccine group, there were 975 primary outcome events (883 hospitalizations for cardiovascular or pulmonary causes and 92 deaths from any cause) among 884 participants during 3577 participant-seasons (event rate, 45 per 100 patient-years), whereas in the standard-dose quadrivalent vaccine group, there were 924 primary outcome events (846 hospitalizations for cardiovascular or pulmonary causes and 78 deaths from any cause) among 837 participants during 3577 participant-seasons (event rate, 42 per 100 patient-years) (hazard ratio, 1.06 [95% CI, 0.97-1.17]; P = .21). In the high-dose vs standard-dose groups, vaccine-related adverse reactions occurred in 1449 (40.5%) vs 1229 (34.4%) participants and severe adverse reactions occurred in 55 (2.1%) vs 44 (1.7%) participants. CONCLUSIONS AND RELEVANCE: In patients with high-risk cardiovascular disease, high-dose trivalent inactivated influenza vaccine, compared with standard-dose quadrivalent inactivated influenza vaccine, did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations. Influenza vaccination remains strongly recommended in this population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02787044.
引用
- Vardeny O, Kim K, Udell JA, et al. Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. JAMA. 2021. PMID: 33275134. doi:10.1001/jama.2020.23649
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。